An Atlanta company developing treatments for blinding diseases of the eye traces its roots to the research facilities at Lions Eye Institute for Transplantation & Research.
Clearside Biomedical (Nasdaq: CLSD), which raised about $50 million in an initial public offering in June, was built on technology developed in the Ybor City facility.
As Lions Eye Institute prepares to strengthen its research initiatives, Clearside’s experience exemplifies how the organization can grow the life sciences sector…
An Atlanta company developing treatments for blinding diseases of the eye traces its roots to the research facilities at Lions Eye Institute for Transplantation & Research.
Clearside Biomedical (Nasdaq: CLSD), which raised about $50 million in an initial public offering in June, was built on technology developed in the Ybor City facility.
As Lions Eye Institute prepares to strengthen its research initiatives, Clearside’s experience exemplifies how the organization can grow the life sciences sector…